A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
ApexOnco Front Page
Recent articles
With a slashed valuation the newly listed biotech heads for phase 3.
As pivotal data approach, the French group pays $210m for ex-US rights.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
